• Effects Of Genetic Mutations Become Knowable With ‘Super Minigene’ System

    Bio-IT World | Molecular biologists at Iowa State University report the potential for the effects of genetic mutations to be known using a “super minigene” system developed in the lab of Ravindra Singh, Ph.D., professor of biomedical sciences.

    Apr 11, 2024

  • Novel Predictive Model For Explaining How Anti-Fibrotic Drugs Work

    Bio-IT World | In drug discovery, the focus of machine learning and artificial intelligence tools has been on predicting outcomes without explanation or understanding of the biochemical pathways mediating those effects. But rigorous translation requires a solid science-based foundation to explain how a drug works, not just that it does.

    Apr 10, 2024

  • NVIDIA GTC Panel Explores the Role of Generative AI in Medicine

    Bio-IT World | During the NVIDIA GTC conference held at the San Jose Convention Center and online March 18-21, NVIDIA CEO Jensen Huang highlighted an array of advancements, including new foundation models coming to NVIDIA BioNeMo, a collaboration with Johnson & Johnson MedTech to expand AI’s role in surgical settings, and the launch of over two dozen generative AI microservices to advance areas like digital health, medical technology, and drug discovery.

    Apr 9, 2024

  • Bio-IT World Names 2024 Best of Show Finalists, People’s Choice Contenders

    Bio-IT World | Bio-IT World announced the 2024 Best of Show Finalists and People’s Choice Contenders today, highlighting 26 new products from 27 different companies that will be on display at the Bio-IT World Conference and Expo, April 15-17, in Boston. The Best of Show Awards will honor several new products live at the event during the Best of Show Awards Reception beginning at 5:15 on Tuesday, April 16.

    Apr 8, 2024

  • Enhancing CRISPR: Utilizing Single-Cell Multiomics for CRISPR-based Drug Product Analysis

    Bio-IT World | The pace at which CRISPR has transitioned from a research tool to a therapeutic modality is remarkable. Initially targeting genetic diseases, CRISPR holds tremendous promise across various indications, rapidly expanding into oncology and infectious diseases, indicating CRISPR's vast and continual evolution as a modality.

    Apr 5, 2024